ALEJANDRA CABRAL: Open Payments
NPI 1699222620 · SAN MARCOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$527 in 19 payments from 9 companies in 2025. Trend: 2023 $306 · 2024 $328 · 2025 $527
Food & beverage: $527
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 1 | $117 |
| Xeris Pharmaceuticals, Inc. | 4 | $76 |
| Novo Nordisk Inc | 3 | $75 |
| GlaxoSmithKline, LLC. | 3 | $75 |
| Lilly USA, LLC | 3 | $61 |
| Edwards Lifesciences Corporation | 1 | $43 |
| SCILEX PHARMACEUTICALS INC. | 2 | $40 |
| Madrigal Pharmaceuticals | 1 | $24 |
| ViiV Healthcare Company | 1 | $15 |
Products named: Yeztugo, SHINGRIX, GVOKE HYPOPEN, MOUNJARO, SAPIEN 3 Ultra RESILIA, ELYXYB - CELECOXIB, Rybelsus, Ozempic.
Industry payments across CA — which companies pay providers there.
